Background: To evaluate the construct and criterion validity of the Tuebingen Cushing's disease quality of life inventory (Tuebingen CD-25) for application in patients treated for Cushing's disease (CD). Methods: A total of 176 patients with adrenocorticotropin hormone-dependent CD (144 of them female, overall mean age 46.1 ± 13.7 years) treated at 3 large tertiary referral centers in Germany were studied. Construct validity was assessed by hypothesis testing (self-perceived symptom reduction assessment) and contrasted groups (patients with vs. without hypercorticolism). For this purpose, already existing data from 55 CD patients was used, representing the hypercortisolemic group. Criterion validity (concurrent validity) was assessed in relation to the Cushing's quality of life questionnaire (CushingQoL), the Short Form 36 health survey (SF-36), and the body mass index (BMI). Results: Patients with self-perceived remarkable symptom reduction had significant lower Tuebingen CD-25 scores (i.e. better health-related quality of life) than patients with self-perceived insufficient symptom reduction (p < 0.05). Similarly, the mean scores of the Tuebingen CD-25 scales were lower in patients without hypercortisolism (total score 27.0 ± 17.2) compared to those with hypercortisolism (total score 45.3 ± 22.1; each p < 0.05), providing evidence for construct validity. Criterion validity was confirmed by the correlations between the Tuebingen CD-25 total score and the CushingQoL (Spearman's coefficient -0.733), as well as all scales of the SF-36 (Spearman's coefficient between -0.447 and -0.700). Conclusion: The analyses presented in this large-sample study provide robust evidence for the construct and criterion validity of the Tuebingen CD-25.

Keywords:
Cushingߣs disease, Validity, Tuebingen Cushingߣs disease quality of life inventory, Cushingߣs quality of life questionnaire, Short Form 36
1.
Orth DN: Cushing's syndrome. N Engl J Med 1995;332:791-803.
2.
Feelders RA, Pulgar SJ, Kempel A, Pereira AM: The burden of Cushing's disease: clinical and health-related quality of life aspects. Eur J Endocrinol 2012;167:311-326.
3.
Sonino N, Bonnini S, Fallo F, Boscaro M, Fava GA: Personality characteristics and quality of life in patients treated for Cushing's syndrome. Clin Endocrinol 2006;64:314-318.
4.
Milian M, Teufel P, Honegger J, Gallwitz B, Schnauder G, Psaras T: The development of the Tuebingen Cushing's disease quality of life inventory (Tuebingen CD-25). 2. Normative data from 1,784 healthy people. Clin Endocrinol (Oxf) 2012;76:861-867.
5.
Milian M, Honegger J, Teufel P, Wolf A, Psaras T: Tuebingen CD-25 is a sensitive tool to investigate health-related quality of life in Cushing's disease patients in the course of the disease. Neuroendocrinology 2013;98:188-199.
6.
van Aken MO, Pereira AM, Biermasz NR, van Thiel SW, Hoftijzer HC, Smit JW, Roelfsema F, Lamberts SW, Romijn JA: Quality of life in patients after long-term biochemical cure of Cushing's disease. J Clin Endocrinol Metab 2005;90:3279-3286.
7.
Webb SM, Badia X, Barahona MJ, Colao A, Strasburger CJ, Tabarin A, van Aken MO, Pivonello R, Stalla G, Lamberts SW, Glusman JE: Evaluation of health-related quality of life in patients with Cushing's syndrome with a new questionnaire. Eur J Endocrinol 2008;158:623-630.
8.
Ware JE Jr, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). 1. Conceptual framework and item selection. Med Care 1992;30:473-483.
9.
Zigmond AS, Snaith RP: The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-370.
10.
Milian M, Teufel P, Honegger J, Gallwitz B, Schnauder G, Psaras T: The development of the Tuebingen Cushing's disease quality of life inventory (Tuebingen CD-25). 1. Construction and psychometric properties. Clin Endocrinol (Oxf) 2012;76:851-860.
11.
Angermeyer MC, Kilian R, Matschinger H: WHOQoL-100 und WHOQoL-BREF - Handbuch für die deutschsprachige Version der WHO Instrumente zur Erfassung von Lebensqualität. Göttingen, Hogrefe, 2000.
12.
Kreitschmann-Andermahr I, Psaras T, Tsiogka M, Starz D, Kleist B, Siegel S, Milian M, Kohlmann J, Menzel C, Fuhrer-Sakel D, Honegger J, Sure U, Muller O, Buchfelder M: From first symptoms to final diagnosis of Cushing's disease: experiences of 176 patients. Eur J Endocrinol 2015;172:285-289.
13.
Carluccio A, Sundaram NK, Chablani S, Amrock LG, Lambert JK, Post KD, Geer EB: Predictors of quality of life in 102 patients with treated Cushing's disease. Clin Endocrinol (Oxf) 2015;82:404-411.
14.
Santos A, Resmini E, Martinez-Momblan MA, Crespo I, Valassi E, Roset M, Badia X, Webb SM: Psychometric performance of the CushingQoL questionnaire in conditions of real clinical practice. Eur J Endocrinol 2012;167:337-342.
15.
Rabin R, de Charro F: EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-343.
16.
Badia X, Roset M, Valassi E, Franz H, Forsythe A, Webb SM: Mapping CushingQoL scores to EQ-5D utility values using data from the European Registry on Cushing's Syndrome (ERCUSYN). Qual Life Res 2013;22:2941-2950.
17.
Lew-Starowicz M, Rola R: Sexual dysfunctions and sexual quality of life in men with multiple sclerosis. J Sex Med 2014;11:1294-1301.
18.
Pozzo MJ, Mociulsky J, Martinez ET, Senatore G, Farias JM, Sapetti A, Sanzana MG, Gonzalez P, Cafferata A, Peloche A, Lemme L: Diabetes and quality of life: initial approach to depression, physical activity, and sexual dysfunction. Am J Ther 2014, E-pub ahead of print.
© 2015 S. Karger AG, Basel
2015
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.